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Objective – Platelet inhibition is a major strategy to prevent acute ischemic cardiovascular 
and cerebrovascular events which may, however, be associated with an increased bleeding 
risk. The (hem)ITAM-bearing platelet receptors, GPVI and CLEC-2, might be promising 
antithrombotic targets as they can be depleted from circulating platelets by antibody 
treatment leading to sustained antithrombotic protection but only moderately increased 
bleeding times in mice.  
Approach and Results - We investigated whether both (hem)ITAM-bearing receptors can 
be targeted simultaneously, and what the in vivo consequences of such a combined 
therapeutic GPVI/CLEC-2 deficiency are. We demonstrate that isolated targeting of either 
GPVI or CLEC-2 in vivo does not affect expression or function of the respective other 
receptor. Moreover, simultaneous treatment with both antibodies resulted in the sustained 
loss of both GPVI and CLEC-2 while leaving other activation pathways intact. However, 
GPVI/CLEC-2-depleted mice displayed a dramatic hemostatic defect and profound 
impairment of arterial thrombus formation. Furthermore, a strongly diminished hemostatic 
response could also be reproduced in mice genetically lacking GPVI and CLEC-2.  
Conclusion - These results demonstrate that GPVI and CLEC-2 can be simultaneously 
downregulated in platelets in vivo and reveal an unexpected functional redundancy of the two 
receptors in hemostasis and thrombosis. These findings may have important implications of 
the potential use of anti-GPVI and/or anti-CLEC-2 based agents in the prevention of 
thrombotic diseases. 
Key Words: platelets, GPVI, CLEC-2, hemostasis, thrombosis 
 
 
 
Bender et al.                                    Platelets deficient in GPVI and CLEC-2 
 
 
 3 
 
Introduction 
At sites of vessel wall injury components of the extracellular matrix (ECM), most importantly 
collagens, are exposed to the flowing blood which triggers sudden platelet activation and 
platelet plug formation, followed by coagulant activity and the formation of fibrin-containing 
thrombi that occlude the site of injury. These events are crucial to prevent posttraumatic 
blood loss but they are also a major pathomechanism in arterial thrombosis.1, 2 Glycoprotein 
VI (GPVI) is the central platelet activating collagen receptor and is non-covalently associated 
with the FcRγ-chain that carries an immunoreceptor tyrosine activation motif (ITAM). Binding 
of GPVI to exposed subendothelial collagens finally results in platelet activation and 
subsequent thrombus growth.3 Patients4 and mice5-8 lacking GPVI display defective platelet 
responses to collagen but only mild bleeding tendencies making this receptor a potential 
target for effective and safe antithrombotic therapy.9 We have previously shown that in vivo 
treatment of mice with anti-GPVI antibodies leads to downregulation of the receptor from the 
surface of circulating platelets by internalization and ectodomain shedding involving multiple 
proteases resulting in a GPVI knockout-like phenotype and long-term anti-thrombotic 
protection but only very moderate effects on normal hemostasis.10, 11 A comparable antibody-
mediated GPVI depletion has also been observed in platelets of autoimmune patients who 
had developed anti-GPVI antibodies4 or in human platelets circulating in NOD/SCID mice.12  
Another receptor that mediates strong platelet activation is CLEC-2, a C-type lectin-like type 
II transmembrane receptor that was identified as the receptor for the platelet activating snake 
venom rhodocytin.13 Interestingly, CLEC-2 is a so-called hemITAM receptor containing only a 
single cytoplasmic YXXL motif that uses a similar signaling pathway as the GPVI/FcRγ-chain 
complex.14 Upon CLEC-2 engagement, hemITAM phosphorylation of CLEC-2 is mediated by 
the tyrosine kinase Syk which is essential for signaling and downstream phosphorylation of 
effector proteins, including PLCγ2.15 A developmental role for CLEC-2, which is the receptor 
for the lymphatic endothelial cell expressed protein podoplanin, has been described as the 
constitutive CLEC-2 knockout led to embryonic/neonatal lethality in mice caused by blood-
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lymphatic misconnection and severe edema.16-18 However, how platelets mediate vessel 
separation is at present unclear and still controversially discussed.18-20  
Principally, CLEC-2 might become a target for antithrombotic agents, but the lethality of 
CLEC-2 knockout mice has made studies on the function of the receptor in hemostasis and 
thrombosis difficult.17, 21 We have demonstrated that CLEC-2 can also be downregulated in 
platelets by in vivo administration of a monoclonal anti-CLEC-2 antibody (INU1). Such CLEC-
2-depleted mice display reduced thrombus stability and are protected from vessel occlusion 
in thrombosis models but show only moderately increased bleeding times.22 Shortly later, two 
studies reported partially conflicting results on the role of CLEC-2 in hemostasis and 
thrombosis using chimeric mice lacking CLEC-2 in the hematopoietic system (Clec2-/-) 
suggesting a significant or no involvement of the receptor in these processes.17, 21 
Here we investigated whether the simultaneous targeting and thus downregulation of GPVI 
and CLEC-2, which are the only (hem)ITAM coupled receptors in mouse platelets,23 is 
possible and what the functional consequences of such a treatment are. We show that both 
receptors can be specifically downregulated simultaneously. Remarkably, loss of both 
(hem)ITAM receptors resulted in severely defective hemostasis and arterial thrombus 
formation, revealing partially redundant functions of GPVI and CLEC-2 in vivo.  
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Results 
Independent and Simultaneous Downregulation of GPVI and CLEC-2 in vivo 
Mice were injected intravenously with the anti-GPVI antibody JAQ1 (100 µg), the anti-CLEC-
2 antibody INU1 (200 µg), or both antibodies in combination. While JAQ1 treatment induced 
a rapidly reversible thrombocytopenia, a more sustained thrombocytopenia was observed in 
mice treated with INU1 or JAQ1/INU1 with recovery to normal platelet counts on day 5-6 
(Figure 1A). JAQ1 treatment induced the complete loss of GPVI but had no effect on CLEC-2 
surface expression levels. Similarly, INU1 treatment induced the complete loss of CLEC-2 
from the platelet surface but had no effect on GPVI expression (Figure 1B). Moreover, CRP-
induced GPVI signaling in CLEC-2-depleted platelets was not affected and also, vice versa, 
CLEC-2 signaling induced by rhodocytin was unaltered in GPVI-depleted platelets (Figure 
1C). Platelets from mice treated with JAQ1 and INU1 specifically lacked GPVI and CLEC-2 
whereas expression of other surface proteins was not or only slightly (GPIX, integrin α2β1) 
altered (Figure 1D). Slightly increased size of double deficient platelets was observed on 
days 5-7 which is in agreement with general observations made after antibody-induced 
thrombocytopenia (Figure 1D). Double-deficient platelets were specifically refractory to the 
GPVI and CLEC-2 agonists CRP, convulxin and rhodocytin, respectively (Figure 1E, integrin 
activation, left; P-selectin exposure, right). Only slightly decreased P-selectin exposure after 
thrombin stimulation was observed at early (Figure 1E) but not later time points (not shown), 
in line with previous observations made in JAQ1-treated mice.24 Similarly, double-deficient 
platelets showed absent aggregation responses to GPVI- or CLEC-2 specific agonists, 
whereas the cells normally aggregated in response to other agonists (Supplemental Figure 
I). These data clearly show that targeting of one (hem)ITAM bearing receptor specifically 
downregulates its expression and activity on the platelet surface but does not influence the 
expression and signaling induced pathway of the other respective (hem)ITAM bearing 
receptor. Moreover, it is possible via simultaneous injection of both antibodies, JAQ1 and 
INU1, to completely shut off ITAM signaling in mouse platelets without affecting signaling by 
G protein-coupled receptors.  
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Severely Defective Hemostasis and Arterial Thrombus Formation in GPVI/CLEC-2 
Double Depleted Mice  
We have previously shown that JAQ1-treated mice display very mildly prolonged bleeding 
times and also INU1-treated mice show only moderately increased but generally more 
variable tail bleeding times in the filter paper model10, 22 and this was confirmed in the current 
study (Supplemental Figure II). Remarkably, however, the depletion of both (hem)ITAM-
bearing receptors lead to a virtually complete loss of hemostatic activity as evident by the 
lack of cessation of tail bleeding (Figure 2A). The same observation was made when the 
wound of the tail tip was immersed in 37°C prewarmed saline. Here, single-deficient mice 
displayed normal hemostatic function, whereas double-deficient mice displayed again a 
strong bleeding phenotype (Figure 2B). Importantly, however, we did not observe any signs 
of spontaneous bleeding in any of these animals. These data suggest that GPVI and CLEC-2 
may have at least partially redundant roles in hemostasis but that their simultaneous loss 
does not induce spontaneous hemorrhage. 
The effect of single and double receptor depletion on pathologic thrombus formation was 
studied by intravital fluorescence microscopy of ferric chloride-injured mesenteric arterioles.7, 
22 In control mice, small aggregate formation was observed at 7.8 ± 1.2 minutes after injury 
(Figure 2C, left) with complete vessel occlusion occurring at 16.4 ± 2.2 minutes (not shown, 
Supplemental video I). GPVI and CLEC-2 single-depleted mice showed similar kinetics of 
small aggregate formation whereas in most cases the vessels did not occlude (GPVI-
depleted: 8/12; Supplemental video II; CLEC-2-depleted: 7/10; Supplemental video III, see 
also references7, 22). Remarkably, onset of small aggregate formation was significantly 
delayed in GPVI/CLEC-2-depleted mice (Figure 2C, left) and the maximal vessel stenosis 
reached within the 40 minutes observation period was strongly reduced compared to all other 
groups (Figure 2C, right). As a consequence, blood flow was maintained in all vessels 
(12/12, Supplemental video IV). Representative images from the experiment are shown 
(Figure 2C). These data demonstrate that the lack of both GPVI and CLEC-2 results in 
almost completely abolished thrombus formation suggesting partially redundant functions of 
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the two receptors in vivo and that their simultaneous targeting provides profound 
antithrombotic protection but also severely impairs normal hemostasis 
 
Defective Hemostasis in CLEC-2 Depleted Gp6-/- Mice 
The severe hemostatic defect in JAQ1/INU1-treated wild-type mice indicated that the 
"therapeutic" depletion of either receptor may induce bleeding in individuals genetically 
deficient in or expressing very low levels of the respective other receptor. To test this 
hypothesis directly, we studied platelet function in newly generated Gp6-/- mice 
(Supplemental Figure III) on day 5 after vehicle or INU1 treatment. As expected, Gp6-/- 
platelets were refractory to GPVI specific agonists as measured by flow cytometry and 
aggregometry whereas responses to other agonists were normal (not shown). In contrast, 
platelets from Gp6-/-/INU1-treated mice lacked GPVI and CLEC-2 (Figure 3A) and were 
unresponsive towards CRP, convulxin, and rhodocytin, whereas all other tested activation 
pathways were unaffected (Figure 3B). Slightly increased GPIb expression levels were 
noted, which may be explained by the slightly increased platelet size. Similar to double-
depleted mice (Figure 2A, B), CLEC-2-depleted Gp6-/- mice showed a severe hemostatic 
defect in both bleeding time assays (Filter paper: Figure 3C, Saline: Figure 3D) mirroring the 
JAQ1/INU1 antibody-induced double-deficiency.  
 
Defective Hemostasis in Mice Genetically Deficient in Platelet GPVI and CLEC-2  
To test the possibility that side effects of the antibody treatment contributed to the observed 
bleeding phenotype in receptor depleted animals, we generated mice genetically deficient in 
both receptors in platelets. As mice constitutively lacking CLEC-2 die perinatally,17, 21 Clec-
2fl/fl, Pf4-Cre mice specifically lacking CLEC-2 in megakaryocytes and platelets were used for 
analysis.18 However, as previously described these mice are not healthy in that they display a 
pronounced defect in blood-lymph separation (Figure 4A)16-18, 20 and other vascular defects 
which may influence the hemostatic system as indicated by a reduction in platelet count to 
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approximately 70% of control (Figure 4B). Platelets of Clec-2fl/fl, Pf4-Cre mice lacked CLEC-2 
whereas all other tested surface receptors were normally expressed (Figure 4C). 
Consequently, rhodocytin-induced platelet activation was abolished in the mutant cells 
whereas responses to other agonists were fully intact (Figure 4D, integrin activation and P-
selection exposure and Supplemental Figure IV: aggregometry). We have previously shown 
that CLEC-2 single-depleted mice display normal small aggregate formation in FeCl3-injured 
mesenteric arterioles but were in most cases unable to fully occlude the vessels.22 Similarly, 
Clec-2fl/fl, Pf4-Cre mice showed only slightly but not significantly delayed first appearance of 
small thrombi (Figure 4E, left) and vessel occlusion was in most of the animals delayed or 
absent (Figure 4E, right and Supplemental Videos V and VI). These results indicated that 
antibody-induced and genetic loss of platelet CLEC-2 provides comparable protection from 
occlusive thrombus formation. 
We intercrossed Gp6-/- and Clec-2fl/fl mice and thereafter mated Gp6-/-/Clec-2fl/fl females with 
with Gp6-/-/Clec-2fl/fl, Pf4-Cre males to obtain double deficient animals. These breedings only 
yielded small litters (2-6 mice) and <35% Gp6-/-/Clec-2fl/fl, Pf4-Cre mice indicating increased 
embryonic or perinatal lethality. The surviving Gp6-/-/Clec-2fl/fl, Pf4-Cre animals displayed 
dramatically altered vascular structure and blood-filled lymphatics in the intestine and this 
phenotype was clearly more pronounced than in CLEC-2 single deficient mice (Supplemental 
Figure V). Flow cytometric analysis confirmed the absence of both receptors in the platelets 
of Gp6-/-/Clec-2fl/fl, Pf4-Cre mice which was associated with some minor changes in the 
expression pattern of other surface receptors and a moderately reduced platelet count similar 
to that observed in CLEC-2 single deficient mice (Figure 5A). As expected, the platelets of 
these mice showed a complete loss of (hem)ITAM signaling as revealed by measurement of 
αIIbβ3 activation and P-selection expression with GPVI or CLEC-2 specific agonists while 
leaving activation of these pathways by ADP, thromboxane and thrombin receptors intact 
(Figure 5B). In addition, we studied GPIb function in GPVI and CLEC-2 deficient platelets by 
two different assays, namely platelet spreading on a vWF coated matrix25 and platelet 
adhesion on vWF under flow conditions.26 In both cases, there was no significant difference 
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as compared to control indicating intact GPIb function in the mutant platelets (data not 
shown). 
To test the effect of genetic GPVI/CLEC-2 double deficiency on hemostasis, tail bleeding 
times in mutant and control mice were assessed by the filter paper model (Figure 5C) and 
the saline model (Figure 5D). Gp6-/-/Clec-2fl/fl, Pf4-Cre mice showed in both models markedly 
prolonged bleeding times as compared to control or single-deficient mice confirming that 
GPVI and CLEC-2 have unexpected redundant roles in normal hemostasis. The bleeding 
time prolongation was less pronounced than in double-depleted mice, which may at least 
partially be explained by the vascular alterations and the reduced general state of health in 
these animals. 
Attempts to study thrombus formation by intravital microscopy in FeCl3-injured mesenteric 
arterioles as shown for GPVI/CLEC-2 depleted mice (which displayed no vessel separation 
defect [Supplemental Figure VI]), failed for Gp6-/-/Clec-2fl/fl, Pf4-Cre mice because of a 
dramatically altered vascular structure and blood-filled lymphatics in the intestine of these 
animals (Supplemental Figure V).  
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Discussion 
In this study we have shown that the two major (hem)ITAM receptors, GPVI and CLEC-2, 
can be simultaneously depleted with high specificity in circulating platelets in vivo and that 
their combined loss results in a severe hemostatic defect and virtually abolished thrombus 
formation in mice. These findings reveal for the first time that GPVI and CLEC-2 have 
partially redundant functions in normal hemostasis and pathological thrombus formation and 
that their simultaneous targeting may be an effective, but not necessarily safe antithrombotic 
approach. 
Both activatory receptors have been proposed as possible pharmacological targets for 
antithrombotic therapy because they can easily be immunodepleted from circulating platelets 
in vivo resulting in a knockout-like phenotype for the respective receptor for a prolonged 
period of time.10, 22 Such a targeted downregulation of GPVI or CLEC-2 provides profound 
antithrombotic protection in different models of thrombosis while having only (very) moderate 
effects on normal hemostasis.7, 10, 17, 21, 22 In this study, we could confirm these previous 
findings and show that the antibody induced loss of either GPVI or CLEC-2 does not affect 
expression or function of the respective other receptor. This appears to be different to the 
previously described phenomenon in human platelets in which cross-inhibition between GPVI 
and another ITAM-bearing receptor, FcγRIIa, which is only present on human but not mouse 
platelets, was observed.23 Gardiner et al. showed27 that FcγRIIa-ligation resulted in 
metalloproteinase-mediated ectodomain shedding of GPVI in vitro, demonstrating that 
signaling by one ITAM-bearing receptor not only influences its own expression and signaling 
but also causes effects on the other ITAM-bearing receptor. This suggests that this “trans-
inhibition” effect of FcγRIIa and GPVI in human platelets in vitro occurs through a mechanism 
that is not operating in the regulation of CLEC-2 and GPVI in mouse platelets in vivo. 
Recently, a role for FcγRIIa as a functional conduit for αIIbβ3-mediated outside-in signaling 
and thus in controlling thrombosis was described in human platelets.28 
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The antibody-induced downregulation of GPVI occurs through two different pathways, 
namely internalization/degradation and more importantly metalloproteinase-dependent 
ectodomain shedding.11, 29 Both processes require signaling through the FcRγ-chain ITAM29 
and can occur in circulating platelets and presumably also in megakaryocytes.10 This GPVI 
immunodepletion appears to be very specific as GPVI-depleted and Gp6-/- mice display 
virtually identical defects in different thrombosis models and a comparable minor 
prolongation of tail bleeding times.7 In contrast, much less is known about the mechanisms 
underlying the antibody-induced loss of CLEC-2 in platelets which is associated with a 
prolonged phase of marked thrombocytopenia.22 It is currently not clear whether the induced 
loss of CLEC-2 can occur in circulating platelets in the periphery or also in megakaryocytes 
and whether it is mediated by ectodomain shedding, internalization or another, yet undefined 
mechanism. However, very similar to the loss of GPVI, CLEC-2 depletion is a surprisingly 
specific process leaving G protein-coupled receptor signaling pathways largely intact (Figure 
1B, C and data not shown).22 We have previously shown that CLEC-2 depleted mice display 
variable tail bleeding times when assessed in the filter paper model, which was also 
confirmed here (Supplemental Figure IIB).22 In contrast to this, we have also reported that 
radiation chimeric mice lacking CLEC-2 in the hematopoietic system have unaltered tail 
bleeding times compared to wild-type controls when assessed using a version of the tail 
bleeding assay which monitors the time to cessation of bleeding without the use of filter 
paper.21 Interestingly, we also found no prolongation of tail bleeding times in CLEC-2 
depleted mice using a third version of this assay, namely monitoring bleeding into saline 
(Figure 2B), suggesting that the mechanisms contributing to hemostasis in the various 
bleeding time models may be partially different and that CLEC-2 depletion very well mirrors 
genetic loss of CLEC-2 in platelets. This is further corroborated by the observation that Clec-
2fl/fl, Pf4-Cre mice show a very similar thrombus formation defect as CLEC-2 depleted mice as 
revealed by intravital microscopy using the ferric chloride injury model (Figure 4E and 
Supplemental Videos V and VI).22 We tested whether the thrombus formation defect in 
CLEC-2 deficient mice could be due to a defect in fibrinogen binding. However, we found no 
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differences between CLEC-2 depleted and control platelets when assessing spreading on a 
fibrinogen coated surface, adhesion under flow on a fibrinogen matrix (rate: 1000 s-1; data 
not shown)30 or aggregation in response to ADP, thromboxane and thrombin receptor 
activation. Together, the data indicate that the targeted depletion of GPVI or CLEC-2 in 
circulating platelets can be induced in a highly specific manner and reproduces the 
phenotypes observed in mice with genetic deletions of these receptors. 
The simultaneous injection of both antibodies, JAQ1 and INU1, resulted in a highly selective 
and complete loss of GPVI and CLEC-2 in platelets, respectively, while leaving other 
activation pathways largely intact. This demonstrates for the first time that it is possible to 
completely delete (hem)ITAM receptor function in circulating platelets in vivo. Further, the 
normal platelet count in these animals demonstrates that neither receptor is required for the 
steady level of platelet production. We found that the combined loss of GPVI and CLEC-2 
resulted in markedly impaired hemostasis and a severe thrombus formation defect that by far 
exceeded that seen in GPVI- or CLEC-2 single depleted animals (Figure 2). Possible off-
target effects of the antibody treatment do likely not explain this pronounced defect as it was 
fully reproduced in CLEC-2-depleted Gp6-/- mice and in Gp6-/-/Clec-2fl/fl, Pf4-Cre mice, although 
to a somewhat lesser extent in the latter which most likely could be due to the mixture of their 
blood and lymph (Figure 3C, D and 5C, D) and other vascular defects that may account for 
their increased embryonic/perinatal lethality and reduced general state of health at the adult 
stage. This assumption is also corroborated as neither the coagulation system (aPTT and 
PT, Supplemental Figure VII) was impaired nor relevant cytokine levels were released in 
double depleted mice (Supplemental Figure VIII) further excluding off-target effects of 
antibody treatment. Together, these findings demonstrate that GPVI and CLEC-2 have 
partially redundant functions in hemostasis and occlusive thrombus formation but the exact 
underlying mechanisms remain to be determined. For normal hemostasis, however, classic 
(hem)ITAM signaling downstream of the two receptors appears not to be essential as mice 
lacking Syk, a crucial proximal molecule in this signaling pathway, did not show such a 
bleeding defect.31 Similarly, it has been reported that the Syk inhibitor, PRT060318, did not 
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affect hemostasis in mice.32 Together, these findings point to functions of GPVI, CLEC-2 or 
both receptors in hemostasis and possibly also thrombosis independent of their classic signal 
transduction capacity. Based on this assumption, one may speculate that adhesive functions 
of these receptors and/or their ability to bind and activate putative counter receptors in 
platelets might account for this unexpected activity. However, currently no intravascular 
ligands for GPVI and/or CLEC-2 are known but based on our results we postulate that they 
may exist. 
Taken together, we have demonstrated that antibody-mediated independent and 
simultaneous downregulation of the platelet activating proteins, GPVI and CLEC-2, is 
possible and revealed unexpected redundant functions of these two receptors in arteriolar 
thrombus formation but also, and more importantly, in normal hemostasis in mice. Although 
data obtained in mice cannot be directly extrapolated to the human system (which is further 
complicated by the possible role of a third ITAM receptor, FcγRIIa, which is absent in the 
mouse genome), these results indicate that anti-GPVI or anti-CLEC-2 treatment might bear 
the risk of uncontrolled bleeding in patients exhibiting defects in the respective other 
(hem)ITAM signaling pathway. Supporting data come from a very recent study that has 
appeared during revision of this manuscript showing that the ITAM receptors, GPVI and 
CLEC-2, are critical for vascular integrity in inflammatory processes.33 Our results may have 
important implications for the development of anti-GPVI and/or anti-CLEC-2 based 
antithrombotic therapeutics. 
. 
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Significance 
Platelet inhibition is a major strategy to prevent acute ischemic cardiovascular and 
cerebrovascular events, which may, however, be associated with an increased bleeding risk. 
The receptors, GPVI and CLEC-2, that are the only (hem)ITAM bearing receptors in mouse 
platelets, might be promising antithrombotic targets as they can be depleted from circulating 
platelets by antibody treatment leading to sustained antithrombotic protection but only 
moderately increased bleeding times in mice. Here, we found that combined loss of GPVI 
and CLEC-2, and thus (hem)ITAM signaling, resulted in markedly impaired hemostasis and a 
severe thrombus formation defect that by far exceeded that seen in GPVI- or CLEC-2 single 
depleted animals. These results indicate that anti-GPVI or anti-CLEC-2 treatment might bear 
the risk of uncontrolled bleeding in patients exhibiting defects in the respective other 
(hem)ITAM signaling pathway. Our results may have important implications for the 
development of anti-GPVI and/or anti-CLEC-2 based antithrombotic therapeutics. 
 
Figure Legends 
Figure 1. Analysis of mice deficient in GPVI and CLEC-2 upon antibody injection.  
A, Mice were intravenously injected with 100 µg JAQ1 and/or 200 µg INU1 in sterile PBS and 
platelet counts were determined on a FACSCalibur at the indicated time points post injection. 
Results are mean ± SD in % of control animals (n = 5 mice per group, representative for 2 
individual experiments). B, D, Flow cytometric analysis of surface protein expression five 
days post injection with the indicated antibodies. Platelets were stained for 15 minutes at 
room temperature with the indicated fluorophore-labeled antibodies and directly analyzed. 
Platelet count in number of platelets/µL. Platelet size is given as mean FSC and was 
determined by FSC characteristics. Results are mean fluorescence intensities (MFI) ± SD (n 
= 5, representative of at least three independent measurements). *, P < 0.05; **, P < 0.01; 
***, P < 0.001. C, E, Flow cytometric analysis of integrin αIIbβ3 activation (JON/A-PE) and 
degranulation-dependent P-selectin exposure on platelets on day 5 post injection. Washed 
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blood was incubated with the indicated agonists for 15 minutes and analyzed on a 
FACSCalibur. Results are mean ± SD (n = 5 mice per group, representative of three 
independent experiments). ***, P < 0.001. ADP: 10 µM; U46619: 3 µM; thrombin: 0.01 U/mL; 
rhodocytin: 1 µg/mL; CRP: 10 µg/mL; convulxin: 1 µg/mL. All experiments were performed on 
day 5-6 after antibody injection. 
 
Figure 2. Determination of hemostatic function and pathological thrombus formation in 
GPVI/CLEC-2-depleted mice.  
A, A 1 mm segment of the tail tip was cut and bleeding was determined to have ceased 
when no blood drop was observed on the filter paper. Each symbol represents one 
individual. B, A 1 mm segment of the tail tip was cut and the tail tip was immersed in saline. 
Each symbol represents one individual. Differences of bleeding times between wt, single 
GPVI-depleted and single CLEC-2-depleted mice are non-significant. C, Mesenteric 
arterioles were treated with 20% FeCl3 and adhesion and thrombus formation of fluorescently 
labeled platelets were monitored by in vivo fluorescence microscopy. Statistical evaluation of 
the time to appearance of a first thrombus (left) and percentage of maximal vessel stenosis 
(right) are depicted. n ≥10. At most 2 arterioles of each mouse were analyzed. ** P< 0.01; *** 
P < 0.001. Vessel stenosis was determined by measuring maximal thrombus size divided by 
vessel diameter using the Metamorph software (Visitron). Representative images are shown. 
White asterisk indicates occluded vessel. All experiments were performed on day 5-6 after 
antibody injection. 
 
Figure 3. Analysis of Gp6-/-/CLEC-2-depleted mice.  
A, Flow cytometric analysis of surface protein expression of Gp6-/- platelets five days post 
injection with the anti-CLEC-2 antibody INU1. Platelets were stained for 15 minutes at room 
temperature with the indicated fluorophore-labeled antibodies and directly analyzed. Platelet 
count in number of platelets/µL. Platelet size is given as mean FSC and was determined by 
FSC characteristics. Results are mean fluorescence intensities (MFI) ± SD (n = 5, 
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representative of at least three independent measurements). **, P < 0.01; ***, P < 0.001. B, 
Flow cytometric analysis of degranulation-dependent P-selectin exposure and integrin αIIbβ3 
activation on platelets. Washed blood was incubated with the indicated agonists for 15 
minutes at RT and analyzed on a FACSCalibur. Results are mean ± SD (n = 5 mice per 
group, representative of three individual experiments). ***, P < 0.001. ADP: 10 µM; U46619: 
3 µM; thrombin: 0.01 U/mL; rhodocytin: 1 µg/mL; CRP: 10 µg/mL; convulxin: 1 µg/mL. C, A 1 
mm segment of the tail tip was cut and bleeding was determined to have ceased when no 
blood drop was observed on the filter paper. Each symbol represents one individual. 
Differences of bleeding times between control, Gp6-/- mice and CLEC-2-depleted mice are 
non-significant. D, A 1 mm segment of the tail tip was cut and the tail tip was immersed in 
saline. Each symbol represents one individual. All experiments were performed on day 5-6 
after antibody injection. Bleeding time of Gp6-/-/CLEC-2-depleted mice is significantly 
prolonged compared to control and Gp6-/- mice ***, P < 0.001 and to CLEC-2-depleted mice 
**, P < 0.01. Bleeding time of CLEC-2-depleted mice is prolonged compared to control **, P < 
0.01. 
 
Figure 4. Analysis of megakaryocyte/platelet-specific CLEC-2 deficient mice.  
A, Representative images of the intestine are shown. L= lymphatic vessel, A= arteriole, V= 
vein. B, Platelet count was determined by flow cytometric analysis. ***, P < 0.001. C, Flow 
cytometric analysis of surface protein expression. Platelets were stained for 15 minutes at 
room temperature with the indicated fluorophore-labeled antibodies and directly analyzed. 
Platelet size is given as mean FSC and was determined by FSC characteristics. Results are 
mean fluorescence intensities (MFI) ± SD (n = 4, representative of at least three independent 
measurements). ***, P < 0.001. D, Flow cytometric analysis of degranulation-dependent P-
selectin exposure and integrin αIIbβ3 activation on platelets. Washed blood was incubated 
with the indicated agonists for 15 minutes at RT and analyzed on a FACSCalibur. Results 
are mean ± SD (n = 5 mice per group, representative of three individual experiments). *, P < 
0.05; ***, P < 0.001. ADP [µM]; U46619: [µM]; thrombin: [U/mL]; rhodocytin: [µg/mL]; CRP: 
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[µg/mL]; convulxin: [µg/mL]. E, Mesenteric arterioles were treated with 20% FeCl3 and 
adhesion and thrombus formation of fluorescently labeled platelets were monitored by in vivo 
fluorescence microscopy. Evaluation of the time to appearance of a first thrombus (left) and 
time to vessel occlusion (right) are depicted. n ≥10. Time of first appearance of thrombi is 
non-significant. Time to occlusion is *, P < 0.05. 
 
Figure 5. Analysis of GPVI and CLEC-2 double mutant mice.  
A, Flow cytometric analysis of surface protein expression of Gp6-/-/ Clec-2fl/fl, Pf4-Cre platelets. 
Platelets were stained for 15 minutes at room temperature with the indicated fluorophore-
labeled antibodies and directly analyzed. Platelet count in number of platelets/µL. Platelet 
size is given as mean FSC and was determined by FSC characteristics. Results are mean 
fluorescence intensities (MFI) ± SD (n = 5, representative of at least three independent 
measurements). *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, Flow cytometric analysis of 
degranulation-dependent P-selectin exposure and integrin αIIbβ3 activation on platelets. 
Washed blood was incubated with the indicated agonists for 15 minutes at RT and analyzed 
on a FACSCalibur. Results are mean ± SD (n = 4 mice per group, representative of three 
individual experiments). **, P < 0.01; ***, P < 0.001. ADP [µM]; U46619: [µM]; thrombin: 
[U/mL]; rhodocytin: [µg/mL]; CRP: [µg/mL]; convulxin: [µg/mL]. C, A 1 mm segment of the tail 
tip was cut and bleeding was determined to have ceased when no blood drop was observed 
on the filter paper. Each symbol represents one individual. Fisher test: Gp6-/-/ Clec-2fl/fl, Pf4-Cre  
vs. control: 0.0351; Gp6-/-/ Clec-2fl/fl, Pf4-Cre  vs. Clec-2fl/fl, Pf4-Cre: 0.0087. Other conditions non-
significant. D, A 1 mm segment of the tail tip was cut and the tail tip was immersed in saline. 
Each symbol represents one individual. Bleeding time of Gp6-/-/ Clec-2fl/fl, Pf4-Cre mice is 
prolonged compared to control and Clec-2fl/fl, Pf4-Cre  *, P < 0.05. 
 
MATERIALS AND METHODS 
Mice  
Male NMRI and C57BL/6JRj mice 3-6 weeks of age were obtained from Harlan 
(Borchen, Germany) or Janvier (Le Genest St. Isle, France). Animal studies were 
approved by the local authorities (Bezirksregierung Unterfranken). Mice were 
intravenously injected with 100 µg anti-GPVI (JAQ1) and/or with 200 µg anti-CLEC-2 
(INU1) antibody. Gp6-/- mice were generated as described in the supplement. Clec-2fl/fl 1 
and Pf4-Cre2 mice were described earlier.  
 
Reagents and Antibodies  
The anesthetic drugs medetomidine (Pfizer), midazolam (Roche), fentanyl (Janssen-
Cilag), and the antagonists atipamezol (Pfizer), flumazenil (Delta Select) and naloxon 
(Delta Select) were used according to the regulation of the local authorities. High-
molecular-weight heparin (Ratiopharm), Apyrase Grade III, human fibrinogen, ADP 
(Sigma-Aldrich), prostacycline (PGI2, Calbiochem), U-46619 (Enzo Life Sciences), 
thrombin (Roche), collagen (Kollagenreagens Horm; Nycomed), convulxin (Axxora), 
were purchased. Collagen-related peptide (CRP) was generated as previously 
described.3 Rhodocytin was isolated as described.4 JON/A-PE antibody against the 
activated form of integrin αIIbβ3 was from Emfret Analytics. All other antibodies were 
generated and modified in our laboratory as previously described.5, 6 
 
Determination of Platelet Count, Size, Surface Protein Expression and Platelet 
Activation 
To measure platelet size and surface protein expression, heparinized blood was diluted 
1:20 and stained for 15 minutes with saturating amounts of fluorophore-conjugated 
antibodies and immediately analyzed on a FACSCalibur (Becton Dickinson, Heidelberg, 
Germany). For platelet activation, samples were activated with agonists at the indicated 
concentrations, stained with fluorophore-conjugated monoclonal antibodies at saturating 
concentrations for 15 minutes at 37°C and directly analyzed.  
 
Tail Bleeding Time  
Filter paper: Mice were anesthetized and a 1-mm segment of the tail tip was removed 
with a scalpel. Tail bleeding was monitored by gently absorbing blood with filter paper at 
20-second intervals, without making contact with the wound site. When no blood was 
observed on the paper, bleeding was determined to have ceased. Otherwise, 
experiments were stopped after 20 minutes. 
Saline: Mice were anesthetized and 1 mm of the tail tip was cut off. Immediately, tails 
were immersed in 0.9% isotonic saline at 37°C. The time until stop of bleeding (no blood 
flow for longer than 1 minute) was determined. Otherwise, experiments were stopped 
after 10 minutes. 
 
Intravital Microscopy of Thrombus Formation in FeCl3-Injured Mesenteric 
Arterioles 
Mice (15-18 g or 4-5 weeks old) were anesthetized, and the mesentery was exteriorized 
through a midline abdominal incision. Arterioles were visualized with a Zeiss Axiovert 
200 inverted microscope (x10) equipped with a fluorescent lamp source, and a 
CoolSNAP-EZ camera (Visitron). Digital images were recorded and analyzed off-line 
using a Metavue software. Injury was induced by topical application of a 3-mm2 filter 
paper saturated with FeCl3 (20%). Adhesion and aggregation of fluorescently labeled 
platelets (i.v. injection of Dylight-488 conjugated anti-GPIX Ig derivative beforehand) in 
arterioles were monitored for 40 minutes or until complete occlusion occurred (blood flow 
stopped for longer than 1 minute).7 
 
Statistics 
Results from at least 3 experiments per group are presented as mean ± SD. Differences 
between two groups were assessed by Welch's test, whereas differences between more 
than two groups were analyzed by one-way analysis of variance (ANOVA) with 
Dunnett’s T3 as post-hoc test using SPSS Statistics 20. The Fischer’s exact test was 
applied to assess variance in occurrence of occlusion. P-values <0.05 were considered 
statistically significant. 
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Supplemental Methods 
 
Generation of Gp6-/- Mice 
BAC (bacterial artificial chromosome) clones containing the Gp6 region were verified by PCR 
using specific primers against exon 2 and 3 and by physical mapping via Southern blotting 
(data not shown), and used as a PCR template to amplify the homologous arms for the 
generation of the targeting vector. Exon 2 and intron 2 were partially deleted and a marker 
and a neomycin resistance cassette were inserted and fused to exon 3. The targeting vector 
was electroporated into Sv129-derived embryonic stem (ES) cells to obtain homologous 
recombination. Successfully targeted ES cells were injected into C57BL/6 blastocysts. 
Germline transmission was obtained by backcrossing the resulting chimeric mice with 
C57BL/6 mice. Gp6-/- mice with a mixed Sv129/C57BL/6 background were used in this study. 
 
Western Blotting  
Proteins of lysed platelets were separated by SDS-PAGE and blotted onto polyvinylidene 
difluoride membranes. To monitor GPVI protein expression, after blocking the membrane 
was incubated with a HRP-labeled anti-GPVI (JAQ1) antibody and enhanced 
chemoluminiscence (ECL) detection substrate (MoBiTec) was used for visualization. 
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Aggregometry 
Washed platelets (200 µL with 0.5 × 106 platelets/µL) were activated with the indicated 
agonists in the presence of 70 µg/mL fibrinogen and light transmission was recorded on a 
four-channel aggregometer (APACT, Laborgeräte und Analysensysteme, Hamburg) over 10 
minutes and was expressed as arbitrary units with the light transmission of the buffer set at 
100%. 
 
Cytokine ELISA 
Plasma samples were assayed for levels of TNFα, IL-6, IFNγ and IL-1α by ELISA 
(Biolegend, Fell, Germany) according to the manufacturer’s instructions. Samples were 
diluted 1:5 to 1:500 and analyzed using Multiskan EX plate reader with Ascent Software 
(Thermo Scientific, Dreieich, Germany). 
 
Quantification of aPTT and Prothrombin Time 
aPTT and prothrombin time (PT) of mouse plasma was determined by standard methods 
(Siemens Healthcare, Eschborn, Germany) in cooperation with the Zentrallabor University 
Hospital Wuerzburg. 
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Supplemental Figures 
Supplemental Figure I. Representative aggregation curves of GPVI/CLEC-2 depleted 
washed platelets. 
Aggregation studies were performed in buffer containing 70 µg/mL human fibrinogen. 
Thrombin-induced platelet aggregation was performed in the absence of human fibrinogen. 
ADP-induced platelet aggregation was performed with platelet-rich plasma. Representative 
curves of at least three independent measurements are shown. Indicated platelet agonist 
was added after 23 seconds.  
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Supplemental Figure II. Measurement of tail bleeding times in GPVI and CLEC-2 single 
deficient mice. 
Tail bleeding times were determined in A, GPVI-deficient and B, CLEC-2-deficient mice 5-7 
days after either JAQ1 or INU1 antibody injection, respectively. A 1 mm segment of the tail 
tip was ablated and bleeding was determined to have ceased when no blood drop was 
observed on the filter paper. 
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Supplemental Figure III. Generation of Gp6-/- mice.  
A, The scheme depicts detection of Gp6 wild-type (wt) and targeted (ko) bands. The external 
probe (black horizontal bar) recognizes a sequence upstream of exon 1 (E1). Exons are 
represented as black vertical bars. The wild-type band between two HindIII sites is 8.4 kb 
and the targeted band is 7.3 kb. Striped black box: neomycin resistance gene. B, Southern 
blot analysis from tail DNA of wild-type (+/+), targeted heterozygous (+/-) and targeted 
homozygous (-/-)Gp6 mice.  C, Western blot of platelet lysates from control and Gp6-/- mice. 
Whole platelet proteins were separated by SDS-PAGE and immunoblotted with an anti-GPVI 
(JAQ1) antibody. GPIIIa was used as a loading control.  
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Supplemental Figure IV. Representative aggregation curves of washed platelets from Clec-
2 fl/fl, Pf4-Cre mice. 
Representative curves of at least three independent measurements are shown. Indicated 
platelet agonist was added after 23 seconds.  
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Supplemental Figure V. Representative images of the intestine of Gp6-/-/Clec-2 fl/fl, Pf4-Cre 
mice. 
Double mutant animals display dramatically altered vascular structure and blood-filled 
lymphatics in the intestine. V: vein; A: artery; L: lymphatic vessel. 
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Supplemental Figure VI. Representative images of the intestine of JAQ1/INU1 treated  
mice. 
Double depleted animals display normal vascular structure in the intestine. V: vein; A: artery. 
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Supplemental Figure VII. Determination of aPTT and PT in JAQ1 / INU1 treated  and Gp6-/-
/Clec-2 fl/fl, Pf4-Cre mice.  
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Supplemental Figure VIII. Plasma samples from JAQ1/INU1 treated mice were assayed for 
levels of TNFα, IL1α, IL6, and IFNγ by ELISA.  
Only negligible or no cytokine levels were detectable. 
h: hours; d: days; LPS: lipopolysaccharide as positive control. 
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Supplemental Videos. Time Lapse Video of In Vivo Thrombus Formation in Mice. 
Mesenteric arterioles of control mice were exteriorized and endothelial injury was induced by 
application of FeCl3. Platelets were labeled in vivo with a Dylight-488–coupled anti-GPIX Ig 
derivative, and platelet adhesion and thrombus formation was monitored in real time, and 
recorded on an inverted fluorescent microscope (Zeiss Axiovert 200) using a CoolSNAP-EZ 
camera (Visitron; exposure time: 700 ms). Representative video of at least 8 arteries per 
group, 1 second video corresponds to 1 minute recording time. Maximal observation time: 40 
minutes. 
 
Video I: A stable occlusive thrombus was formed after ~19 minutes in control mice.  
 
Video II: In GPVI-depleted mice (day 5 post injection), large thrombi were formed which 
continuously embolized due to the lack of GPVI-collagen-interaction.  
 
Video III: In CLEC-2-depleted mice (day 5 post injection), formed thrombi were completely 
instable, little fragments embolized and individual platelet released from the surface of 
growing thrombi. 
 
Video IV: Beginning of platelet aggregate formation of JAQ1/INU1-treated mice (day 5 post 
injection) is clearly delayed. Formed thrombi remain considerably reduced in size and do not 
occlude the vessel. 
 
Video V: A stable occlusive thrombus was formed after ~23 minutes in Clec-2fl/fl mice. 
 
Video VI: Formed thrombi in mesenteric arterioles of Clec-2fl/fl, Pf4-Cre mice were completely 
instable, little fragments embolized and individual platelet released from the surface of 
growing thrombi. 
